<DOC>
	<DOCNO>NCT03093974</DOCNO>
	<brief_summary>The purpose trial investigate use inhaled colistimethate sodium administer twice daily 12 month delay time first pulmonary exacerbation compare placebo subject non-cystic fibrosis ( CF ) bronchiectasis chronically infect P. aeruginosa</brief_summary>
	<brief_title>Trial Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>sign informed consent ; age 18 year old either gender ; diagnose nonCF bronchiectasis computerise tomography ( high resolution CT ) ; least 2 pulmonary exacerbation require oral antibiotic 1 pulmonary exacerbation require intravenous antibiotic 12 month precede Screening Visit ; 1 positive sputum culture P. aeruginosa 12 month precede Screening Visit ; clinically stable require change pulmonary treatment least 30 day Screening Visit ; prebronchodilator Forced Expiratory Volume 1 second ( FEV1 ) ≥30 % predict ; positive sputum culture P. aeruginosa Screening Visit . cystic fibrosis ( CF ) focal endobronchial lesion otherwise curable cause ( e.g . foreign body aspiration ) ; know history hypogammaglobulinaemia require treatment immunoglobulin , inflammatory bowel disease , primary ciliary dyskinesia , myasthenia gravis , porphyria myeloproliferative disease , severe cardiovascular disease ; receive treatment allergic bronchopulmonary aspergillosis ( ABPA ) ; massive haemoptysis ( great equal 300 mL require blood transfusion ) predominant lung condition chronic obstructive pulmonary disease ( COPD ) asthma interstitial lung disease opinion Investigator ; History follow : list transplantation ; significant active illness likely affect patient 's survival within 12 month ; receive longterm domiciliary oxygen therapy noninvasive ventilation management respiratory failure ; current active malignancy , except basal cell carcinoma skin without metastasis , history solid organ bone marrow transplant ; take immunosuppressive medication azathioprine , methotrexate , cyclosporine , tacrolimus , sirolimus , mycophenolate , anti cytokine medication , rituximab ; current diagnosis Mycobacterium tuberculosis infection ; positive culture Mycobacterium abscessus complex , Mycobacterium avium complex , Mycobacterium xenopi , Mycobacterium kansasii , Mycobacterium malmoense Mycobacterium simiae year precede Screening Visit ; current treatment nontuberculous mycobacterial ( NTM ) pulmonary infection consideration NTM treatment next 12 month ; current smoker exsmokers less 6 month prior Screening Visit ; evidence bronchial hyperreactivity may , opinion Investigator , indicate subject able tolerate colistimethate sodium ; therapy long term ( ≥ 30 day ) prednisone stable dose great 15 mg day ( equivalent dose corticosteroid ) prior Screening Visit 1 ; new maintenance treatment oral macrolides ( azithromycin erythromycin ) start within 30 day Screening Visit ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>